Clinical Trial Update: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating the risk of tumor lysis syndrome in adults with previously untreated chronic lymphocytic leukemia receiving venetocla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)
• Venclyxto (Venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: RECRUITING